Comparison of Somavaratan (VRS-317), a Long-acting Human Growth Hormone, to Daily rhGH in a Phase 3, Randomized, One-year, Open-label, Multi-center, Non-inferiority Trial in Pre-pubertal Children with Growth Hormone Deficiency.

Trial Profile

Comparison of Somavaratan (VRS-317), a Long-acting Human Growth Hormone, to Daily rhGH in a Phase 3, Randomized, One-year, Open-label, Multi-center, Non-inferiority Trial in Pre-pubertal Children with Growth Hormone Deficiency.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs Somavaratan (Primary)
  • Indications Growth disorders; Somatotropin deficiency
  • Focus Registrational; Therapeutic Use
  • Acronyms VELOCITY
  • Sponsors Versartis
  • Most Recent Events

    • 13 Oct 2017 This study has been completed in Belgium as per European Clinical Trials Database.
    • 11 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 21 Sep 2017 Results presented in a Versartis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top